Tumor invasion and metastasis regulated by microRNA-184 and microRNA-574-5p in small-cell lung cancer

Oncotarget

Volumn 6, Issue 42, 2015, Pages 44609-44622

  Zhou, Rui ^a   Zhou, Xiaoshu ^a   Yin, Zhongyuan ^a   Guo, Jing ^b   Hu, Ting ^a   Jiang, Shun ^c   Liu, Li ^a   Dong, Xiaorong ^a   Zhang, Sheng ^a   Wu, Gang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b QINGDAO UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Metastasis; miR 184; miR 574 5p; Prognosis; SCLC

Indexed keywords

BETA CATENIN; ENDOTHELIAL PAS DOMAIN PROTEIN 1; MICRORNA; MICRORNA 184; MICRORNA 574 5P; ONCOPROTEIN; PROTEIN TYROSINE PHOSPHATASE RECEPTOR TYPE U; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CTNNB1 PROTEIN, HUMAN; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; MIRN184 MICRORNA, HUMAN; MIRN574 MICRORNA, HUMAN; PTPRU PROTEIN, HUMAN; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE; TUMOR MARKER;

3' UNTRANSLATED REGION; ADULT; ARTICLE; BIOINFORMATICS; BLOOD SAMPLING; CANCER PROGNOSIS; CANCER RISK; CANCER TISSUE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE REPRESSION; GENETIC ASSOCIATION; H2227 CELL LINE; H446 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IN VITRO STUDY; LUNG CANCER CELL LINE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MICROARRAY ANALYSIS; MOLECULAR MODEL; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SMALL CELL LUNG CANCER; TUMOR INVASION; UPREGULATION; BLOOD; CELL MOTION; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; KAPLAN MEIER METHOD; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SECONDARY; SMALL CELL LUNG CARCINOMA; TIME FACTOR; TREATMENT OUTCOME; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BETA CATENIN; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; PROPORTIONAL HAZARDS MODELS; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 2; SIGNAL TRANSDUCTION; SMALL CELL LUNG CARCINOMA; TIME FACTORS; TRANSFECTION; TREATMENT OUTCOME;

EID: 84953392681     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6338     Document Type: Article

References (52)

1. Riaz SP, Lüchtenborg M, Coupland VH, Spicer J, Peake MD and Møller H. Trends in incidence of small cell lung cancer and all lung cancer. Lung Cancer. 2012; 75:280-284.
2. Ries L, Eisner M, Kosary C, Hankey B, Miller B, Clegg L, Mariotto A, Feuer E and Edwards B. SEER Cancer Statistics Review, 1975-2004. National Cancer Institute; Bethesda, MD: 2007. Available at: seer cancer gov/csr/1975-2001. 2007.
3. Videtic GM, Stitt LW, Dar AR, Kocha WI, Tomiak AT, Truong PT, Vincent MD and Edward WY. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. Journal of Clinical Oncology. 2003; 21:1544-1549.
4. Wolfson AH, Bae K, Komaki R, Meyers C, Movsas B, Le Pechoux C, Werner-Wasik M, Videtic GM, Garces YI and Choy H. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. International Journal of Radiation Oncology Biology Physics. 2011; 81:77-84.
5. Foster NR, Qi Y, Shi Q, Krook JE, Kugler JW, Jett JR, Molina JR, Schild SE, Adjei AA and Mandrekar SJ. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer. Cancer. 2011; 117:1262-1271.
6. Ha M and Kim VN. Regulation of microRNA biogenesis. Nature Reviews Molecular Cell Biology. 2014; 15:509-524.
7. Seton-Rogers S. microRNA: Self-regulated transcription. Nature Reviews Cancer. 2014; 14:9-9.
8. Perfetti A, Greco S, Bugiardini E, Cardani R, Gaia P, Gaetano C, Meola G and Martelli F. Plasma microRNAs as biomarkers for myotonic dystrophy type 1. Neuromuscular Disorders. 2014; 24:509-515.
9. Di Leva G, Garofalo M and Croce CM. MicroRNAs in cancer. Annual review of pathology. 2014; 9:287.
10. Schwarzenbach H, Nishida N, Calin GA and Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nature reviews Clinical oncology. 2014; 11:145-156.
11. Zhao J, Du F, Shen G, Zheng F and Xu B. The role of hypoxia-inducible factor-2 in digestive system cancers. Cell death & disease. 2015; 6:e1600.
12. Xue G, Yan H, Zhang Y, Hao L, Zhu X, Mei Q and Sun S. c-Myc-mediated repression of miR-15-16 in hypoxia is induced by increased HIF-2α and promotes tumor angiogenesis and metastasis by upregulating FGF2. Oncogene. 2015; 34:1393-406.
13. Liu Y, Zhu Z, Xiong Z, Zheng J, Hu Z and Qiu J. Knockdown of protein tyrosine phosphatase receptor U inhibits growth and motility of gastric cancer cells. International journal of clinical and experimental pathology. 2014; 7:5750.
14. Zhu Z, Liu Y, Li K, Liu J, Wang H, Sun B, Xiong Z, Jiang H, Zheng J and Hu Z. Protein tyrosine phosphatase receptor U (PTPRU) is required for glioma growth and motility. Carcinogenesis. 2014; 35:1901-1910.
15. Yan H-X, Yang W, Zhang R, Chen L, Tang L, Zhai B, Liu S-Q, Cao H-F, Man X-B and Wu H-P. Protein-tyrosine phosphatase PCP-2 inhibits β-catenin signaling and increases E-cadherin-dependent cell adhesion. Journal of Biological Chemistry. 2006; 281:15423-15433.
16. Liu Z, Hou J, Ren L, He J, Sun B, Sun L-Z and Wang S. Protein tyrosine phosphatase receptor type O expression in the tumor niche correlates with reduced tumor growth, angiogenesis, circulating tumor cells and metastasis of breast cancer. Oncology reports. 2015; 33:1908-1914.
17. Keith B, Johnson RS and Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2012; 12:9-22.
18. Scott A and Wang Z. Tumour suppressor function of protein tyrosine phosphatase receptor-T. Biosci Rep. 2011; 31:303-307.
19. Kim WY, Perera S, Zhou B, Carretero J, Yeh JJ, Heathcote SA, Jackson AL, Nikolinakos P, Ospina B, Naumov G, Brandstetter KA, Weigman VJ, Zaghlul S, Hayes DN, Padera RF, Heymach JV, et al. HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest. 2009; 119:2160-2170.
20. Jansson MD and Lund AH. MicroRNA and cancer. Molecular oncology. 2012; 6:590-610.
21. Allegra A, Alonci A, Campo S, Penna G, Petrungaro A, Gerace D and Musolino C. Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol. 2012; 41:1897-1912.
22. Liu R, Chen X, Du Y, Yao W, Shen L, Wang C, Hu Z, Zhuang R, Ning G and Zhang C. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clinical chemistry. 2012; 58:610-618.
23. Ye Y, Wang Y, Roth J and Wu X. Serum MicroRNAs as biomarkers in early stage non-small cell lung cancer. Cancer Research. 2014; 74:298-298.
24. Wang F, Zheng Z, Guo J and Ding X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol. 2010; 119:586-593.
25. Brase JC, Johannes M, Schlomm T, Falth M, Haese A, Steuber T, Beissbarth T, Kuner R and Sultmann H. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer. 2011; 128:608-616.
26. Wang N, Zhou Y, Zheng L and Li H. MiR-31 is an independent prognostic factor and functions as an oncomir in cervical cancer via targeting ARID1A. Gynecol Oncol. 2014; 34:129-37.
27. Toiyama Y, Hur K, Tanaka K, Inoue Y, Kusunoki M, Boland CR and Goel A. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg. 2014; 259:735-743.
28. Teixeira AL, Ferreira M, Silva J, Gomes M, Dias F, Santos JI, Maurício J, Lobo F and Medeiros R. Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients. Tumor Biology. 2014; 35:4057-4066.
29. Yang M, Liu R, Sheng J, Liao J, Wang Y, Pan E, Guo W, Pu Y and Yin L. Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of esophageal squamous cell carcinoma. Oncol Rep. 2013; 29:169-176.
30. Ji S, Ye G, Zhang J, Wang L, Wang T, Wang Z, Zhang T, Wang G, Guo Z and Luo Y. miR-574-5p negatively regulates Qki6/7 to impact β-catenin/Wnt signalling and the development of colorectal cancer. Gut. 2013; 62:716-26.
31. Foss KM, Sima C, Ugolini D, Neri M, Allen KE and Weiss GJ. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol. 2011; 6:482-488.
32. Ranade AR, Cherba D, Sridhar S, Richardson P, Webb C, Paripati A, Bowles B and Weiss GJ. MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer. J Thorac Oncol. 2010; 5:1273-1278.
33. Li Q, Li X, Guo Z, Xu F, Xia J, Liu Z and Ren T. MicroRNA-574-5p was pivotal for TLR9 signaling enhanced tumor progression via down-regulating checkpoint suppressor 1 in human lung cancer. PLoS ONE. 2012; 7:e48278.
34. Wong T-S, Liu X-B, Wong BY-H, Ng RW-M, Yuen AP-W and Wei WI. Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clinical Cancer Research. 2008; 14:2588-2592.
35. Wong T-S, Ho W-K, Chan J, Ng R and Wei WI. Mature miR-184 and squamous cell carcinoma of the tongue. ScientificWorldJournal. 2009; 9:130-132.
36. Wu GG, Li WH, He WG, Jiang N, Zhang GX, Chen W, Yang HF, Liu QL, Huang YN, Zhang L, Zhang T and Zeng XC. Mir-184 post-transcriptionally regulates SOX7 expression and promotes cell proliferation in human hepatocellular carcinoma. PLoS ONE. 2014; 9:e88796.
37. Foley NH, Bray IM, Tivnan A, Bryan K, Murphy DM, Buckley PG, Ryan J, O'Meara A, O'Sullivan M and Stallings RL. MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Mol Cancer. 2010; 9:83.
38. Zhen Y, Liu Z, Yang H, Yu X, Wu Q, Hua S, Long X, Jiang Q, Song Y, Cheng C, Wang H, Zhao M, Fu Q, Lyu X, Chen Y, Fan Y, et al. Tumor suppressor PDCD4 modulates miR-184-mediated direct suppression of C-MYC and BCL2 blocking cell growth and survival in nasopharyngeal carcinoma. Cell Death Dis. 2013; 4:e872.
39. Liu Z, Mai C, Yang H, Zhen Y, Yu X, Hua S, Wu Q, Jiang Q, Zhang Y, Song X and Fang W. Candidate tumour suppressor CCDC19 regulates miR-184 direct targeting of C-Myc thereby suppressing cell growth in non-small cell lung cancers. J Cell Mol Med. 2014; 18:1667-79.
40. Hausser J and Zavolan M. Identification and consequences of miRNA-target interactions [mdash] beyond repression of gene expression. Nature Reviews Genetics. 2014; 15:599-612.
41. Wang H, Lian Z, Lerch MM, Chen Z, Xie W and Ullrich A. Characterization of PCP-2, a novel receptor protein tyrosine phosphatase of the MAM domain family. Oncogene. 1996; 12:2555-2562.
42. Yan HX, Yang W, Zhang R, Chen L, Tang L, Zhai B, Liu SQ, Cao HF, Man XB, Wu HP, Wu MC and Wang HY. Protein-tyrosine phosphatase PCP-2 inhibits beta-catenin signaling and increases E-cadherin-dependent cell adhesion. J Biol Chem. 2006; 281:15423-15433.
43. Scrima M, De Marco C, De Vita F, Fabiani F, Franco R, Pirozzi G, Rocco G, Malanga D and Viglietto G. The nonreceptor- type tyrosine phosphatase PTPN13 is a tumor suppressor gene in non-small cell lung cancer. Am J Pathol. 2012; 180:1202-1214.
44. Keith B, Johnson RS and Simon MC. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nature Reviews Cancer. 2011; 12:9-22.
45. Kim WY, Perera S, Zhou B, Carretero J, Yeh JJ, Heathcote SA, Jackson AL, Nikolinakos P, Ospina B and Naumov G. HIF2α cooperates with RAS to promote lung tumorigenesis in mice. The Journal of clinical investigation. 2009; 119:2160-2170.
46. Choi H, Chun Y-S, Kim T-Y and Park J-W. HIF-2α enhances β-catenin/TCF-driven transcription by interacting with β-catenin. Cancer research. 2010; 70:10101-10111.
47. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127:469-480.
48. Huber AH and Weis WI. The structure of the beta-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by beta-catenin. Cell. 2001; 105:391-402.
49. Nelson WJ and Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science. 2004; 303:1483-1487.
50. Saydam O, Shen Y, Wurdinger T, Senol O, Boke E, James MF, Tannous BA, Stemmer-Rachamimov AO, Yi M, Stephens RM, Fraefel C, Gusella JF, Krichevsky AM and Breakefield XO. Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Mol Cell Biol. 2009; 29:5923-5940.
51. Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Müller SC and Ellinger J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology. 2011; 77:1265. e1269-1265. e1216.
52. Zhou H, Mu X, Chen J, Liu H, Shi W, Xing E, Yang K and Wu G. RNAi silencing targeting RNF8 enhances radiosensitivity of a non-small cell lung cancer cell line A549. International journal of radiation biology. 2013; 89:708-715.